VENMAX DRUGS AND PHARMACEUTICA
Latest filings
Next results: Thu, 12 Nov · Financial Results- Board meeting set to approve September quarter results · Results
- Shareholders approve Hatri Pharma amalgamation with Venmax · Strategic Transactions
- Shareholders meet on Hatri Pharma merger; voting results pending · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹9 Cr over the trailing twelve months.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from VENMAX DRUGS AND PHARMACEUTICA's filed financials and exchange disclosures
What does VENMAX DRUGS AND PHARMACEUTICA do?
VENMAX DRUGS AND PHARMACEUTICA is a Pharmaceuticals & Biotechnology company listed on BSE.
Is VENMAX DRUGS AND PHARMACEUTICA profitable?
Yes. Over the trailing twelve months VENMAX DRUGS AND PHARMACEUTICA reported a net profit of ₹0.28 Cr on revenue of ₹9.29 Cr.
Does VENMAX DRUGS AND PHARMACEUTICA pay a dividend?
Not in the latest reported year — VENMAX DRUGS AND PHARMACEUTICA's dividend payout for FY26 was nil.
Is VENMAX DRUGS AND PHARMACEUTICA debt-free?
On a net basis, yes. It reported borrowings of ₹0.28 Cr on its 31 Mar 2026 balance sheet, but holds ₹0.94 Cr more cash than debt.
Is VENMAX DRUGS AND PHARMACEUTICA expensive compared with its peers?
On trailing P/E, VENMAX DRUGS AND PHARMACEUTICA ranks 92 of 160 in Pharmaceuticals — cheaper than 43% of them, against an industry median of 29.3×. This is a position, not a valuation judgement.
How much does the VENMAX DRUGS AND PHARMACEUTICA share price move in a day?
On a typical session VENMAX DRUGS AND PHARMACEUTICA moves 2.73% — that is the median absolute close-to-close move across its last 266 trading days. MarketPing measures each filing's price reaction against it.
When are VENMAX DRUGS AND PHARMACEUTICA's next results?
Financial Results on Thu, 12 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track VENMAX DRUGS AND PHARMACEUTICA's announcements?
Every NSE and BSE filing by VENMAX DRUGS AND PHARMACEUTICA appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.